

AMENDMENTS TO THE CLAIMS:

This listing of the claims will replace, without prejudice, all prior versions and listings of claims in the application.

1. - 2. (Cancelled).

3. (Original) The hybridoma cell line with DSMZ accession number DSM ACC2625.

4. (Original) The anti-idiotypic antibody expressed by the hybridoma cell line of claim 3.

5. (Original) A humanized antibody having the binding specificity of the anti-idiotypic antibody of claim 4.

6. (Original) The anti-idiotypic antibody of claim 4, wherein said anti-idiotypic antibody further comprises a detectable agent.

7. - 28. (Cancelled).

29. (Previously Presented) A humanized anti-idiotypic antibody having the 6 CDRs of the anti-idiotypic antibody expressed by the hybridoma cell line with DSMZ accession number DSM ACC2625, wherein the humanized anti-idiotypic antibody specifically binds a polypeptide comprising the SC-1 human monoclonal antibody heavy-chain sequence set forth in SEQ ID NO:1.

30. (Previously Presented) The humanized anti-idiotypic antibody of claim 29, wherein said antibody further comprises a detectable agent.

31. (Cancelled).